The Technical Analyst
ENDRA Life Sciences Inc [NDRA]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
ENDRA Life Sciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.39% $0.248
America/New_York / 19 apr 2024 @ 12:45
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.73 mill |
| EPS: | -1.580 |
| P/E: | -0.160 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 11.04 mill |
| Avg Daily Volume: | 0.176 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.160 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.160 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.383 (54.89%) $0.136 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.123 - 0.365 ( +/- 49.53%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-02 | Basenese Lou | Buy | 600 | Stock Options |
| 2024-01-02 | Harsh Michael | Buy | 600 | Stock Options |
| 2024-01-02 | Digiandomenico Anthony | Buy | 600 | Stock Options |
| 2024-01-02 | Tokman Alexander Y | Buy | 600 | Stock Options |
| 2023-05-18 | Thornton Michael Milos | Buy | 15 000 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 100 transactions |
| Buy: 3 706 167 | Sell: 432 712 |
Forecast:
14:26 - $0.244
Live Trading Signals (every 1 min)
Forecast
1: 12:56 - $0.247
Forecast 2: 13:46 - $0.246
Forecast 3: 14:26 - $0.244
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.248 (5.39% ) |
| Volume | 0.0263 mill |
| Avg. Vol. | 0.176 mill |
| % of Avg. Vol | 14.95 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NDRA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NDRA
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Latest Press Releases
2024-03-28 16:05:00 - Press Release
Endra Life Sciences Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
Ann arbor, mich.--(business wire)---- $ndra #nalfd--endra life sciences inc. (nasdaq: ndra), a pioneer of thermo acoustic enhanced ultrasound (taeus®), today reports financial results for the three months and year ended december 31, 2023 and provides a business update. highlights from the fourth quarter of 2023 and recent weeks include: installed first taeus system in the uk at king's college hospital for clinical evaluation. king's college hospital nhs foundation trust (kch) in london is one of the leading cen.
2024-03-21 08:00:00 - Press Release
Endra Life Sciences To Report Fourth Quarter 2023 Financial Results On March 28, 2024
Ann arbor, mich.--(business wire)---- $ndra #nalfd--endra life sciences inc. (endra) (nasdaq: ndra), a pioneer of thermo acoustic enhanced ultrasound (taeus®), today announced that the company will report financial results for the three months and year ended december 31, 2023 on thursday, march 28, 2024 after the close of trading on the u.s. financial markets. management will host a conference call and webcast beginning at 4:30 p.m. eastern time to discuss the results, provide an update on recent corporate deve.
2024-02-14 08:30:00 - Press Release
Endra Life Sciences Bolsters Taeus® System Intellectual Property With New Patents In U.s., China And Europe
Ann arbor, mich.--(business wire)---- $ndra #nalfd--endra life sciences inc. (nasdaq: ndra), a pioneer of thermo acoustic enhanced ultrasound (taeus®), announces the issuance of three new patents, including one in the u.s., one in china and one in europe. endra's intellectual property portfolio now includes 74 issued patents worldwide providing protection for the taeus system with its novel thermoacoustic technology. these patents protect novel innovations integral to the taeus system, ensuring maximum radiofre.
2023-11-29 08:00:00 - Press Release
Endra Life Sciences Secures 39th U.s. Patent For Taeus® System Technology
Ann arbor, mich.--(business wire)---- $ndra #nafld--endra life sciences inc. (nasdaq: ndra), a pioneer of thermo acoustic enhanced ultrasound (taeus®), announces that the united states patent and trademark office has issued to endra a new patent, u.s. patent no. 11828727 (the ‘727 patent) titled “thermoacoustic probe.” the ‘727 patent relates to a thermoacoustic probe design with an optical transducer and an integrated wedge, which helps to minimize unwanted signals and optimizes radiofrequency signals to the t.
2023-11-27 08:00:00 - Press Release
Endra Life Sciences To Participate In The Benchmark Company's 12th Annual Discovery One-on-one Investor Conference
Ann arbor, mich.--(business wire)---- $ndra #nalfd--endra life sciences inc. (nasdaq: ndra), a pioneer of thermo acoustic enhanced ultrasound (taeus®), announces that management will be participating in the benchmark company's 12th annual discovery one-on-one investor conference being held thursday, december 7, 2023 at the new york athletic club in new york city. management will be holding one-on-one meetings with investors. to schedule a one-on-one meeting with endra, you may submit your request online via the.
Latest News
2024-03-28 21:10:17 - Seeking Alpha
ENDRA Life Sciences Inc. (NDRA) Q4 2023 Earnings Call Transcript
2023-11-14 22:14:08 - Seeking Alpha
ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman and Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Third Quarter 2023 Financial Results Conference Call. All participants will be in a listen-only mode.
2023-11-07 16:05:00 - Business Wire
ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three and nine months ended September 30, 2023 on Tuesday, November 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate d.
2023-08-14 21:44:09 - Seeking Alpha
ENDRA Life Sciences Inc. (NDRA) Q2 2023 Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman and Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.
2023-05-15 21:48:05 - Seeking Alpha
ENDRA Life Sciences Inc. (NDRA) Q1 2023 Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Francois Michelon - Chairman & Chief Executive Officer Michael Thornton - Chief Technology Officer Irina Pestrikova - Senior Director of Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Inc. First Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.
2023-04-28 09:09:24 - InvestorPlace
Why Is ENDRA Life Sciences (NDRA) Stock Down 16% Today?
ENDRA Life Sciences (NASDAQ: NDRA ) stock is sliding lower on Friday after revealing details of its public offering. ENDRA Life Sciences is offering up 862,500 shares of NDRA stock alongside 431,250 warrants to purchase more shares.
2023-03-14 19:31:02 - Seeking Alpha
ENDRA Life Sciences Inc. (NDRA) Q4 2022 Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q4 2022 Earnings Conference Call March 14, 2023 4:30 PM ET Company Participants Yvonne Briggs – LHA Investor Relations Francois Michelon – Chairman and Chief Executive Officer Michael Thornton – Chief Technology Officer Irina Pestrikova – Senior Director-Finance Conference Call Participants Vernon Bernardino – H.C. Wainwright & Company Edward Woo – Ascendiant Capital Operator Good afternoon, and welcome to the ENDRA Life Sciences Incorporated Fourth Quarter 2022 Financial Results Conference Call.
2023-03-07 16:05:00 - Business Wire
ENDRA Life Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 14, 2023
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months and year ended December 31, 2022 on Tuesday, March 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m.
2022-11-14 18:31:06 - Seeking Alpha
ENDRA Life Sciences Inc. (NDRA) Q3 2022 Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Yvonne Briggs - Investor Relations Francois Michelon - Chairman & Chief Executive Officer Michael Thornton - Chief Technology Officer Renaud Maloberti - Chief Commercial Officer Irina Pestrikova - Senior Director of Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Third Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode.
2022-08-15 19:56:19 - Seeking Alpha
ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q2 2022 Results - Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Yvonne Briggs - IR Francois Michelon - Chairman and CEO Mike Thornton - Chief Technology Officer Renaud Maloberti - CCO Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Vernon Bernardino - H.C. Wainwright Operator Good day everyone, and welcome to the ENDRA Life Sciences' Second Quarter 2022 Financial Results Conference Call.